Highlights Newsletter 5

This newsletter presents you the following key sessions:

1. PODCAST with dr. Deepu Madduri about the phase 1b/2 CARTITUDE-1 study, examining ciltacabtagene autoleucel
    in relapsed/refractory multiple myeloma

2. Haematopoietic cell transplantation also recommended in older patients with advanced high-risk myelodysplastic
    syndrome with a suitable donor

3. Blinatumomab: a new standard in the consolidation therapy for children with high-risk acute lymphoblastic
    leukaemia patients in first relapse

4. CRISPR-based gene editing with CTX001 as a potential functional cure for transfusion-dependent β-thalassemia
    and sickle cell disease

5. Ruxolitinib outperforms the current best available therapy for patients with steroid-refractory/dependent chronic
    graft-versus-host disease